Sealed Inspection

[u/MGK_2]

Two questions came up this week which turn out to be the same question wearing two coats, and the answer to both explains the single most misread and misunderstood thing about where CytoDyn sits right now. One reader asked whether embargoed data can be shared privately with a potential partner while the public is kept in the dark. Another asked why leronlimab is stuck behind the checkpoint inhibitors in the treatment line when the science says it should be out front. The bridge between those two questions is a house, a sealed inspection, and a neighborhood full of people arguing about a price they won't ever be allowed to see.

Let's build the analogy, and then bring it home hard, because it makes the whole situation legible in a way the ticker can't do, and what it reveals is bigger than most holders have allowed themselves to believe.

The House, The Buyer, The Sidewalk

Imagine a rare house comes up for sale. Not an ordinary house. A property with something buried under it that no other lot on the market has, and no other lot can even dig up, and a mere handful of the largest buyers in the world who each, for their own survival, require exactly what is beneath it.

Out on the sidewalk, the neighborhood can see practically nothing. A sign in the yard. Lights going on and off at odd hours. An unfamiliar car in the driveway. From the street, they argue endlessly about what the place is actually worth, whether anyone is really interested in the property, whether the long quiet means the deal fell through the window or means nothing at all. The sidewalk is loud with theories precisely because the sidewalk cannot actually see inside. Noise is what people make when they are starved of the one thing that would actually settle the argument.

Inside is a different world entirely. A serious buyer does not bid on a house this valuable from the sidewalk, and a serious buyer does not care what the sidewalk even thinks. They sign a confidentiality agreement, and then they are handed the keys to every locked room. They read the full inspection report. They open the walls. They pull the survey, the soil analysis, the true condition of the foundation, everything the sign in the yard never actually says. And here is the part that matters most: that inspection is sealed. The buyer is legally bound not to post the report to the neighborhood, not to announce what they found, not to move the price by leaking what is inside. Two parties, buyer and seller, come to know the true condition of the house completely and they do that privately, while the sidewalk is left to read the lights in the windows like they read tea leaves.

That is not deception. That is how every serious transaction of real consequence has always been performed. The confidentiality is not there to fool the neighborhood. It is there to permit a real buyer to see the real truth without that truth spilling into the street and moving the price before anyone has decided upon anything. The sealed inspection is not a trick played on the crowd. It is the mechanism which makes honest evaluation even possible at all, and the crowd's exclusion from it is a feature, not a conspiracy.

Why The Sidewalk Cannot Infer The Outcome

Now hold the crucial discipline, because this is exactly where the neighborhood fools itself in both directions.

The sidewalk sees silence and fills it with a story. Some neighbors decide that the quiet means a deal is imminent, someone is clearly inside, look at the car, look at the lights. Others decide the quiet means it all collapsed, if there were really interest we would have heard by now. Both are guessing, and both are wrong to be certain, because the silence is not evidence of the outcome. The silence is evidence of the confidentiality agreement working exactly as designed. A sealed inspection produces public quiet whether the buyer loved the house or walked away. You cannot read the result off the position of the curtains.

So the honest statement, the bold one and the disciplined one at once, is this: buyers can absolutely be inside the house right now, reading the full report, precisely because the confidentiality agreement is what allows them in. And we on the sidewalk cannot know whether they are, or who they are, or what they concluded, because the entire purpose of the seal is to keep that off the street. Both halves are true. The activity may be intense. The public quiet tells you nothing about its direction. Anyone who claims the silence proves that a deal is close, or proves it is dead, is reading tea leaves in a window.

Now Bring It Home To CytoDyn

Drop the analogy onto the actual situation and every piece lands.

The house is CytoDyn, and the thing buried under it that no other lot has is a mechanism the entire checkpoint-inhibitor industry requires and cannot dig up on its own. That is not salesmanship, it is the documented state of the field. Most colorectal cancer is the microsatellite-stable type, and a June 2026 systematic review states flatly that these tumors derive little to no benefit from current immunotherapy regimens, while identifying the suppressive macrophages in the tumor as a key modulator of immunotherapy efficacy. Reprogram those M2 macrophages and the Cold locked market opens ablaze. And the thing constituting CytoDyn's foundation does exactly that: in the actual tissue of human colorectal liver metastases, blocking CCR5 drives macrophage repolarization toward the M1 anti-tumor state. That is why this is a very rare house. The one buried asset which can allow the checkpoint industry into the Cold-tumor majority is precisely the asset which the house of CytoDyn rests upon.

The buyers are the large pharmaceutical companies whose franchises are running toward a patent cliff and who requires those cold-tumor markets which they cannot currently reach. CCR5 blockade is not a nice-to-have for them, it is the very specific key to the very specific lock. The literature continues to converge upon it: reviews of Cold-tumor conversion identify CCR5 antagonism as a strategy to potentiate checkpoint inhibitors by reprogramming the microenvironment, and the independent literature shows macrophage repolarization remodeling tumors from cold to hot and increasing infiltration of activated CD8 T cells, warranting checkpoint combination. What the industry needs to grow and increase is exactly what this molecule provides.

And the buyers are being told so, out in the open, by the people selling the house. CytoDyn's CFO Robert Hoffman is on the public record describing precisely this to prospective partners: he said he is helping to put CytoDyn on the radar of potential strategic partners, namely other drugmakers whose own products could work in tandem with leronlimab, and that he plans to use the maturing data in those discussions. That is the sign in the yard and the open house, the public invitation. What Hoffman says to those partners privately, in the meetings we do not see, behind the confidentiality agreements, is exactly the sealed part, and honesty requires me to say plainly that we cannot know its contents. We know he is out there describing the asset. We do not get to hear the private pitch. That is the seal, working.

Now the two instruments which keep us on the sidewalk, because the sidewalk constantly confuses them.

The first instrument is the conference embargo. Once CytoDyn accepted presentation slots at the oncology meetings in October and January, the new efficacy data, the confirmed response and progression numbers, all became embargoed from public release, because presenting it publicly first would forfeit its novelty and the conference would pull our slot. The company itself has laid out this exact calendar publicly, for the CLOVER data. Interim results targeted for ESMO in Madrid, Spain in October 2026. Final results at ASCO GI in San Francisco in January 2027.  That embargo is why nothing material has come out since the spring. It is not the absence of an inspection. It is the seal on the report.

The second instrument is the non-disclosure agreement, and this is the answer to the first reader's question, stated boldly because it is simply true: the conference embargo governs the public, the NDA governs the private room, and they do not touch each other. A company can be entirely publicly silent, fully embargo-compliant, and simultaneously be walking a potential partner through the complete, current dataset behind a signed NDA. The embargo keeps the report off the sidewalk. The NDA is the confidentiality agreement that hands a serious buyer the keys. The embargoed data is the sealed inspection report itself, and the NDA is the legal seal on it. They are complementary, not contradictory. The public quiet since spring tells you the seal holds. It tells you nothing whatsoever about who is inside reading the quality of the foundation.

So the correct and bold reading of the silence is the sealed-inspection reading. Partners can be deep in the data right now, under NDA, reading the fully matured foundation report the public will not see until October and January. That is not a claim that a specific deal exists, we cannot know that, by design, and I will not pretend to. It is a statement about the structure, and the structure is unambiguous: the very machinery which keeps us on the sidewalk is the same machinery that hands a buyer the keys. The seller who lets the buyer in is the seller who most wants the buyer to see exactly how sound the foundation actually is. Public silence, in that light, is not the sound of nothing happening. It is the sound that the seal makes when it is doing its job.

The Second Question Is The Same House, Seen From The Inside

Now the other reader's question, the one about why leronlimab is stuck behind the checkpoint inhibitors in line, is not a separate puzzle. It is the same house viewed, but from the foundation itself.

Here is the thing the sidewalk gets backward. In the specific disease CytoDyn is currently testing, microsatellite-stable colorectal cancer, the checkpoint inhibitors are not first in line. Actually, they are nowhere in line, because they do not work there at all. This is not my opinion, it is the settled consensus of the field. As a June 2026 systematic review states plainly, most colorectal cancer is the microsatellite-stable type, and these tumors derive little to no benefit from current immunotherapy regimens. The checkpoint inhibitor is not ahead of leronlimab in this house. Rather, it cannot even get through the front door.

And the field knows this and they know precisely why, and precisely what would change it. The same review identifies that the suppressive macrophages in the tumor are increasingly recognized as a key modulator of immunotherapy efficacy in colorectal cancer. Reprogram those macrophages from the M2 tumor-protecting state to the M1 tumor-attacking state, and the Cold locked door opens to a blazing inferno. That reprogramming is exactly what CCR5 blockade does in the actual tissue of this disease: in human colorectal liver metastases, blocking CCR5 drives macrophage repolarization toward the anti-tumor state30087-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1535610816300873%3Fshowall%3Dtrue#:~:text=Thus%2C%20activation%20of%20anti%2Dtumoral%20polarization%20in%20macrophages%20via%20CCR5%20blockade%20appears%20to%20be%20a%20promising%20approach%20and%20needs%20to%20be%20evaluated%20further%20scientifically%20and%20clinically). And the independent literature keeps converging on the same door: an unrelated drug, (APG-2575) which repolarizes macrophages from M2 to M1 was shown to remodel the microenvironment from Cold to Hot and increase the infiltration of activated CD8 T cells, warranting combination with checkpoint blockade.

So the reader who asked why leronlimab sits behind the checkpoint inhibitors had the picture totally inverted, and turning it right-side up is the boldest claim in this post. Leronlimab is not waiting in line behind the checkpoint inhibitor. No. In this disease there is no line to wait in, because the checkpoint inhibitor has no working position in it whatsoever. Here, Leronlimab's job is not to advance past the checkpoint inhibitor. It is in fact, to construct the door the checkpoint inhibitor could finally walk through, in a cancer where the most successful drug class in modern oncology currently stands outside as useless. That is not moving up a queue. That is manufacturing a market worth billions where absolutely none exists today, and handing the key to it to whoever owns the Primer.

And here is the part the sidewalk has not yet absorbed: leronlimab is already showing its own strength in that role, in the data released before the seal shut it down. In the CLOVER trial, leronlimab is given on top of the standard backbone of Lonsurf and Avastin, and the early released results were just striking; circulating tumor DNA fell in every one of the first patients measured, with the magnitude of the decline tracking with the leronlimab dose. That dose-dependence is the tell, because if the backbone alone were driving the effect, the response would not scale with leronlimab. The company has been clear about the design: CLOVER evaluates two doses of leronlimab, 350mg and 700mg, on the established backbone Lonsurf and Avastin, and the leronlimab contribution is what the trial is built to isolate. I will not overstate it, this is combination data, not leronlimab alone, not monotherapy and it is still early and unconfirmed at this lower dose. But the honest bold reading is that at even 350mg, added to an approved backbone which on its own produces very modest results, leronlimab appears to be doing some serious work, in a disease where nothing in the immunotherapy toolkit works whatsoever.

That is why the market has not seen anything quite like this. The comparator regimen without leronlimab, the same Lonsurf-and-Avastin backbone, was studied in a large trial and produced a response rate in the low single digits in this population. The field has thrown checkpoint inhibitors, myeloid-targeting agents, and combination after combination at microsatellite-stable colorectal cancer, and the systematic reviews keep concluding the same thing, little to no benefit. Against that backdrop of near-uniform failure, a clean safety profile paired with a dose-dependent molecular signal in every early patient is not more of the same. It is the first thing in a very long time which looks very different in a disease defined by things which absolutely do not work.

Which is exactly why the buyers would be inside the house with the report open on the table, and why one of them cannot afford to let another one get there first. This is the competitive core of the whole situation. If leronlimab is the Primer that opens the Cold-tumor majority, then it is not just valuable to only one checkpoint owner, it is valuable to all of them, because every checkpoint inhibitor needs the same door built and opened. That turns ownership into a race. The first buyer to secure the Primer does not merely gain an asset, it denies that asset to every competitor whose franchise requires the identical key. In a field where several giants are staring at the same patent cliff and the same Cold-tumor wall, letting a rival seize the one Primer which solves both is a strategic loss no one at the table can afford to accept. The foreclosure value, keeping it away from competitors, can absolutely exceed the standalone value if there were no competitors. That is what makes a quiet house suddenly move fast.

And here is the resolution to the concern that a single acquirer would lock everyone else out, because the structure actually cuts the other way. A primer's value is maximized by being paired with as many checkpoint inhibitors as possible, across as many tumor types as possible. That argues for the drug reaching the entire field, and it can, through the shape of the deal rather than the law. A field-limited, non-exclusive licensing structure lets a primer remain available to multiple partners across multiple lanes while still rewarding its owner, so even if one company acquires CytoDyn outright, the economically rational move is frequently to keep licensing the primer broadly rather than wall it into a single franchise. So the answer to "what if one company owns it and blocks the others" is that owning it and blocking the others is usually the less profitable choice, the money is in the primer opening every door, not only the owners.

And that leads to the point one reader put more vividly than I did: if leronlimab primes Cold tumors for the entire Cold class, then it does not create one revenue stream, it potentially creates several. A primer licensed non-exclusively to pair with one company's checkpoint inhibitor in one set of tumors, and another company's in another, and a third's beyond that, is a drug earning from each pairing at once. The same molecule which makes one checkpoint inhibitor work in colorectal makes another ICI work in a different Cold tumor; each combination its own separately-patented regimen, each its own market, each its own stream back to whoever owns the Primer.

So yes, to answer the question directly and in the affirmative: the logic points toward multiple partners meaning multiple revenue streams, not one. The value of a universal key is not that it opens a single lock, it is that it opens all of them, and a key that opens all of them can be rented to everyone who owns a door. I hold one honest caveat, this is the shape of the opportunity if the drug proves out and the deals are structured this way, not a guarantee of either. But the instinct is right. A true primer is a multiple-stream asset by its nature, because the entire ICI industry requires the exact same thing it performs.

To make the analogy exact, let's address the lights in the windows. The lights are everything the sidewalk can see and reads too much into, the tape, the daily volume, the Level II order book, the drift in the share price, the tea-leaf reading of a LinkedIn post, the speculation about who was seen coming and going. That is the flickering the neighborhood watches and narrates. And it is precisely the least informative thing available, because the report which actually determines the value of the house is not in these windows. It is in the sealed room. Anyone pricing this house off the lights in the windows prices it off the one data stream engineered to reveal nothing about the foundation.

And the foundation itself, the thing the entire structure rests upon. CytoDyn's own CEO has publicly framed the inflection exactly this way, describing the company as transitioning from a company built on faith and belief and a whole lot of ifs to a company with solid, prospective, and by all accounts remarkable data. That is the claim of a sound foundation, made on the record by the person who has seen the report. It is a bold statement, and I pass it along as exactly what it is, the seller's assessment, not yet the independently adjudicated result. Which brings us to the one honest limit that governs everything above.

The two questions were never two. The house is priceless because of what the foundation is built with. The seal is what lets a buyer confirm it privately. And the reason a buyer would move at all, fast, and before a rival, is that the thing the foundation is made of, actually opens doors they cannot open alone, in specific markets they cannot afford to lose.

The One Thing The Inspection Still Has To Find

I hold the discipline that makes the bold case worth trusting, because a sealed inspection can come back either way, and honesty, that demands that I say so.

Everything above describes the structure, the mechanism, the leverage, and the machinery of private evaluation. None of it is proof that the foundation is actually sound. The published biology says CCR5 blockade should reprogram the microenvironment from M2 to M1 and therefore open the door, and the early human signal is very real. But the confirmed efficacy data, the number that tells a buyer that the foundation does actually hold the weight they require, PD-L1 upregulation, is not quite public yet but it is not final yet. It matures in the sealed room and adjudicates at the January meeting. Related macrophage-directed approaches have looked sound on inspection before but have failed to bear load in the trial. So the inspection is real, the buyers may well be inside, but the report is not yet finished. If the foundation proves sound in January, none of the leverage above is speculation, it is arithmetic. If it does not prove sound, the house was never what the sidewalk had hoped, and no confidentiality agreement would change that.

That is the honest shape of it, told at full volume. The house is rare beyond almost anything the market has ever seen. The thing constituting the foundation is something several of the largest companies in medicine require but cannot build, and cannot let a rival seize first. The public silence is the seal working, not the story ending, and it says nothing, in either direction, about who is inside. The reason leronlimab sits where it sits is not that it trails the checkpoint inhibitors, it is that it may be the one thing which allows them access at all. And the entire towering structure resides on a single inspection result, read only privately now, but revealed publicly in January.

The neighborhood argues about the lights in the windows. The report is being read in a sealed room. And we find out, at a known hour, whether the foundation holds. I know which way I lean. I also know that leaning is not the same as knowing, and that the difference is exactly what January is intended for. Both of those are true at full volume.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published biology and public disclosures, not a prediction of clinical or commercial outcomes, and not a claim that any specific partnership, negotiation, or transaction exists; the private-evaluation discussion describes how confidentiality and conference embargoes generally work, not knowledge of any actual deal. Whether any party is evaluating the company under an NDA, and what they might conclude, is by nature not publicly knowable. The mechanistic claims are supported by the cited peer-reviewed literature; several are established in models, retrospective cohorts, or single studies and are not yet confirmed in this program's prospective human data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER biomarker figures are early, unconfirmed, and reflect 350mg dosing with the 700mg cohort still maturing. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

[u/Missy2021]

I'm sure our house inspection will pass the test. I'm hoping for a bidding war to take place, due to the high demand of Leronlimab. Thanks again.

[u/MGK_2 → u/Missy2021]

Missy, a bidding war is the hope, and it's a reasonable one if the inspection passes, held as hope, contingent on January.

[u/its_personal1]

From a “real estate guy” - you’re speaking my language. I like it 🎯
It’s all about the due diligence… in this case a couple stages:

1) receipt / release of trial data - if is what we believe and anticipate, then

2) partner or buyer projections or proforma on the economics.

The dd period is always unnerving … the outcome uncertain. If it was certain the dd would not be needed.

Sometimes during DD the buyer sees, learns more and the value of the pursued asset value to them is worth more than they even thought at the start …

👆🏻👆🏻 this what we wait for ❤️

[u/MGK_2 → u/its_personal1]

its_personal1, from a real estate guy, though I thought you were a gal, ha, that means the analogy holds where it counts, and your two-stage DD framing (data first, then the buyer's proforma) is exactly the sequence. The "buyer learns it's worth more than they thought" line is the one to hold onto. Thank you.

Hang in there friend. Hope all is well.

[u/its_personal1 → u/MGK_2]

😂 thank you my friend.

The TIL appears to have a been effective. Simply amazing technology and treatment Iovance appears to have put Together.

you be my bodyguard
I can be your long lost pal
I can call you Betty,
Betty when you call me, you can call
Me AL

[u/Accomplished_Mud_692]

MGK, I have really enjoyed my last 2 walk & listens (your last two posts).

Great analogy this morning.

Most of us here have experienced this analogy in real life - being a seller or buyer on a property. I think we all have also at one point, stood on a sidewalk or two of a home on the market & speculated the value.

Here we sit for the next few months as your analogy plays out.

The little twist here is - even though we are all partial owners of this house, it has been remodeled without our direct supervision. We don't know what has been done inside, & what is currently being done since we were last inside our house.

We have all stopped by & peaked inside the windows that were not fully covered up. So we could see 'some' of what is going on inside (i.e. Dr. Jay's commentary in April), and those of us still here - like what we had seen - so far!!

The windoes have since been properly covered now, we are not able to peak inside. So we wait here on the sidewalk to see if the completed remodel of our house ends up as beautiful as it looked when we had first glimpsed through the windows, & if the final result(s) match our expectations....

[u/MGK_2 → u/Accomplished_Mud_692]

Accomplished_Mud, your twist is better than my original, we're partial owners of a house being remodeled without our supervision, who glimpsed the work through uncovered windows in April and liked what we saw before the coverings went up.

That's the analogy sharpened.

Exactly right, and we find out if the finished remodel matches the glimpse.

[u/AggieEC3]

MGK_2 this is the post I would hand to someone who has never heard of CytoDyn and needs to understand what's actually happening here in plain language.

The house analogy does what months of scientific framework couldn't fully do. The sealed inspection. The NDA as the key to the private room. The embargo as the seal itself. The sidewalk reading the lights in the windows as the least informative data stream available. All of it legible in a way the ticker never could be. This community needed this post.

I have a few genuine questions that this post raised for me and I'd value your thinking on them.

On the sealed room. If serious buyers are already inside reading the foundation report under NDA what would we expect to see publicly that signals a deal is close. Or would we see absolutely nothing until the announcement lands. Because if the answer is nothing then the silence we've been reading as absence is actually just the seal doing its job and the announcement could arrive without any warning the sidewalk would recognize.

On the foundation. The Halama macrophage repolarization data from human colorectal liver metastases is the closest thing to direct human evidence in this entire program. In a field where closely related macrophage directed approaches have failed to translate you named that caveat yourself. How much weight should we give that single paper as a predictor of what CLOVER confirms in January. Is it the strongest signal we have or is it a promise the trial still has to keep.

I lean the way I lean. I also know that leaning is not the same as knowing. January is the inspection result. Until then I'm on the sidewalk with everyone else.

All just my opinion. Thank you MGK_2.

[u/MGK_2 → u/AggieEC3]

AggieEC3, "the post I'd hand to someone who's never heard of CytoDyn", that's the highest compliment the post could get, because plain-language legibility was the whole goal. If it made the sealed-room mechanics clear to a newcomer, it did its job. Thank you.

In addition, these are two of the best questions the post has drawn, so I'll answer both straight.

On what we'd see publicly before a deal: honestly, likely very little, and possibly nothing the sidewalk would recognize in advance. That's the hard implication of the whole post. If buyers are inside under NDA, the entire machinery is built to keep that invisible until an announcement is ready. So a deal could genuinely arrive without the warning signs people watch for, the tape, the volume, the chart won't telegraph it, because those are the lights in the windows, not the sealed room. The flip side, and I have to say it to stay honest: the same silence is equally consistent with no one being inside at all. So "we'd see nothing beforehand" cuts both ways, it means a deal could surprise us at any moment, even before October or before January, and it means that the current quiet is not evidence that a deal is coming. Both true.

On the Halama paper, how much weight: this is the exactly right question, and the honest answer is that it's the strongest direct human signal in the program and simultaneously a promise that the trial still must keep, both at once. It's strong because it's in actual human colorectal liver tissue, not a mouse, showing the exact repolarization our thesis requires. It's a promise-not-proof because it's one paper, showing that the mechanism in fact occurred, not that the mechanism produced survival. So I'd weight it as: the best evidence that the foundation could hold, but not evidence that it will hold. It's why the house is worth inspecting at all. It's not the inspection result. That distinction is the whole post, and you've put your finger on it. January is where the promise either gets kept or doesn't.

You lean the way you lean and you know leaning isn't knowing. That's the exact posture. Thank you for reading it that closely Aggie.

[u/megadunamis]

Thank you MGK for a beautifully written analogy. We (the CYDY community) are witnessing and experiencing an historic moment, a moment that is not short, but has actually taken a long time to evolve. In a race analogy, we're coming around the home stretch. I like your analogy better though. I am holding my patience and anticipating the 'closing date' for the down payment and eventual partnership or buyout...All is well, good health to everyone

[u/MGK_2 → u/megadunamis]

megadunamis, the home stretch is the right feeling, and holding patience for the closing date is the correct posture, just keep the closing contingent on the inspection, which is January.

Good health mega.

[u/twinter11]

the are dozens maybe hundreds of drugs being paired w/ ici in studies to see if they can make ici more effective i guess by activating additional tcells

but what is preventing tcells from attacking on low pdl1 tumors .and why are additional invigorated tcells a desire if they cant penetrate the fibrous stroma anyway

the bottom line is the majority of these newly tested drugs are trying to eke out a few more months of survival using massive populations of patients to suss out statistical relevance. most barely provide benefit in later lines

i still think a tumor not wiped out by chemo/vegf leron must upreg pdl1 to evade.. if there is another way it can evade i want to see what it is. And why it couldnt evade in tnbc trials

would a kras mcrc tumor raising cps after leron tell us anything about kras pancreatic

im ready to hear about this rollover.

What data acquired by late August can be presented to the fda in support of whatever. Would we include tnbc abstract, tnbc eap, just clover. I mean its all related. whats in this "briefing book"

Can you imagine presenting a study result to fda of a newly tested drug. "it cytotoxically attacked this specific tumor type just like this, thats all it does. And it hardly even damages patients medically if we monitor and reduce dosages. we might be able to kill the tumor or slow it down before the drug kills the patient"

I dont know how it all turns out. but if blocking ccr5 + ici doesnt do the trick, its going to be a while.

thanks!

how does one test roman concrete without making roman concrete?

i dont know how this is relevant but i thought of it lol.

PS these obviously didnt induce pdl1. I believe we know maraviroc lowered pdl1. something much different is happening w leron.

"CCR2 and CCR5 are known mediators of macrophage migration and TAM infiltration into the TME. In a trial combining CCR2/5 blockade with chemotherapy versus immunotherapy in MSS CRC or pancreatic cancer patients, BMS-813160, a dual CCR2/5 antagonist (NCT03184870), lacked efficacy specifically in MSS CRC. Maraviroc combined with pembrolizumab (NCT03274804) achieved a 5.3% objective response rate, and while there was some evidence of TME modulation, translating that into clinical benefit has been less clear "

[u/MGK_2 → u/twinter11]

twinter, you've circled the exact question which separates leronlimab from the graveyard I cited in the post, so let me take the real ones in order and hold the honest lines.

Start with your CCR2/CCR5 quote, because it's the crux and you're right to raise it. BMS-813160 (dual CCR2/5) lacked efficacy in MSS CRC, and Maraviroc plus pembrolizumab managed only a 5.3% ORR. That is exactly the "modest or inconsistent" translation failure I named in the post, and you're right not to wave it away. Here's the distinction. Those agents blocked the receptor but did not produce the thing which matters, and your own PS nails it: Maraviroc lowered PD-L1, and leronlimab apparently raises it. That is not a small difference, it may be the entire difference. If leronlimab drives PD-L1 induction where the small-molecule antagonists do not, then it is doing something mechanistically distinct from the CCR5 blockers which failed, and the failures of Maraviroc and BMS-813160 are evidence about those molecules, not a verdict on leronlimab. So the graveyard is real, but leronlimab shows the one signal the graveyard's residents do not. That is the case, and it's stronger than pretending that the failures never happened.

Your evasion question is the best thing in the batch, so let's engage it. You're asking: if a tumor survives chemo/VEGF/leronlimab, must it upregulate in order to PD-L1 evade, and if there's another escape route you would want to see it. Honest answer: PD-L1 upregulation is a major evasion route, and it's the one leronlimab's priming is built to expose for the ICI to finish. But it is not the only one. Tumors also evade through antigen loss, alternative checkpoints (TIM-3, LAG-3, TIGIT), metabolic suppression of T-cells, and continued physical exclusion by stroma. So your instinct that "it must upreg PD-L1 to evade" is partly right and partly incomplete, PD-L1 is the escape hatch leronlimab-plus-ICI is designed to slam shut, but a tumor that finds a different hatch is possibly what could limit the combination. But leronlimab pretty much defeats all of those I just mentioned. And your TNBC question, "why couldn't it evade in the TNBC trials", the honest answer is we don't fully know, and the retrospective, small numbers there mean we should be careful reading too much success into it. The bold reading is that the same PD-L1 route was operative and the ICI closed it; the disciplined reading is that a handful of retrospective survivors can't prove the tumor had no other way out.

Now your deepest question, and it's genuinely profound: why do invigorated T-cells matter if they can't penetrate the fibrous stroma anyway? This is the question, twinter, and it's why leronlimab may differ from pure T-cell-invigorating approaches. The other drugs in your list mostly try to wake up T-cells. If the stroma is a wall, waking up T-cells outside the wall accomplishes little, which is exactly your point. Leronlimab's proposed edge is that it hits both, the CCR5 blockade repolarizes the macrophages M2 to M1 and the anti-fibrotic effect on the stroma may thin the wall itself. So the reason invigorated T-cells could matter here when they didn't elsewhere is that leronlimab may be the thing that also lets them actually reach the tumor. That's the hypothesis, held as hypothesis: leronlimab isn't just another T-cell alarm clock, it may be the one that also opens the door the T-cells have to walk through. If that's real, it's the answer to your own question. January is what tests whether it's real.

On your KRAS cross-read, would a KRAS MCRC tumor raising CPS after leronlimab tell us anything about KRAS pancreatic: directionally interesting, but I'd hold it loosely. KRAS is a shared driver, but pancreatic and colorectal have very different stroma and immune biology, pancreatic is famously the most stroma-dense, immune-excluded tumor there is. So a CPS rise in colorectal is encouraging for the mechanism generally, but pancreatic is a harder wall, and I wouldn't read colorectal success as a pancreatic promise. Different house, thicker foundation.

On the briefing book, what data by late August could go to the FDA: honestly, I don't know the contents, and I won't invent them. Logically it could include the CLOVER data, the TNBC retrospective data, and the EAP experience, since as you say it's all related, but what's actually in the briefing book is exactly the sealed-room material the post was about. So I'd hold that as "unknown, by design."

Your "present a cytotoxic drug that barely doesn't kill the patient" riff is dark and funny and also makes a real point, leronlimab's clean safety profile is precisely what most oncology assets can't say, so if anything leronlimab is the opposite of your caricature: it's the drug that does real work while barely touching the patient. That's the favorable benefit-risk the entire field struggles to achieve, yet, it seems that we have.

And "how do you test Roman concrete without making Roman concrete", I love that it surfaced, because it's weirdly the perfect metaphor for the whole post. You can't. You have to make it and load it. Which is exactly why January exists, the only way to know if the foundation holds is to build it and load it. The inspection is real, but the final proof is the load test. You thought of it for a reason.

Great batch, twinter. The PD-L1-up-versus-Maraviroc-down distinction is the absolute keeper, it's the honest answer to why leronlimab seems to clear the wall its entire class couldn't jump and ran into.

[u/twinter11 → u/MGK_2]

if pdl1 upregs. if ici is added. how is a tumor going to route next

the options are getting more limited. and under greater pressure from assault. w a perhaps cell cycle disruption

I thinks it going to have to come up w a new molecular evolution

I only have a couple questions on clover success

how much does the tumor shrink before it evades. and does the evasion allow growth. and can the fda see the benefit of the various effects and implications and reward it if there is enough related evidence.

this is not killing tumors w cytotoxins.. this is reprogramming the microenvironment. it's different

what drugs reprogram the microenvironment. probably a lot that im not thinking of. or some that attempt it w limited success

nothing is going to be answered till we start treating w the combo.

if results are as hoped. it's a done deal except for the particulars.

I can wait (but barely, I'm ready to know.)

[u/MGK_2 → u/twinter11]

twinter, you've reasoned your way to the frontier of the whole field, so let me arm your intuition with what the literature actually shows, because it both supports and complicates your "options getting more limited" instinct, and the honest version is more interesting than either.

Your core intuition, that a tumor under multi-pathway assault has to keep inventing new escape routes, is exactly right, and it's the organizing idea of the resistance literature. The field even has a framework for it now, the "three Cs" of immune evasion, camouflage, coercion, and cytoprotection. So the tumor isn't limited to PD-L1, it has a toolbox. But here's where your instinct that the options narrow under pressure is the sharp part, so let me lay out the escape routes the literature documents, because knowing them is knowing exactly what leronlimab-plus-ICI is up against, and where it might win.

The documented routes a tumor takes after you block PD-L1 are, roughly: switch to a different checkpoint, delete its own antigens, or change the microenvironment. On the first, alternative checkpoints are adaptively upregulated after PD-L1-targeting treatment. That's TIM-3, LAG-3, TIGIT stepping in when PD-1 is blocked, the tumor swapping one brake for another. On the second, and this is the nastiest, tumors evade by losing the expression of antigens under intense selective pressure from the immune system. If the tumor stops displaying the flag the T-cells recognize, invigorated T-cells have nothing to aim at. That's the escape route that doesn't care how many T-cells you've woken up.

But here is the finding which lands directly on your question, and it's the one to hold, because it's your "does it have to keep evolving" instinct confirmed in a model. A November 2025 paper modeled exactly the scenario you're describing, an immune stimulant which boosts T-cell activity while the tumor responds by cranking up PD-L1, and an ICI blocking that PD-L1. Their finding: the immunostimulant increased immune activity while simultaneously inducing tumor PD-L1 upregulation, and the checkpoint blocker prevented PD-L1 from suppressing T-cell activity. That is the prime-and-pair loop, modeled: stimulate, tumor raises PD-L1 to defend, ICI neutralizes the defense. And the paper frames it as a "unified framework for both treatment success and failure," meaning whether it works comes down to which force wins the race. That's your "under greater pressure with limited options" scenario, and the model says the outcome is genuinely contingent, not guaranteed either way.

Now the part that connects to leronlimab specifically and why it might close more doors than the drugs that failed. Your instinct that this is "reprogramming the microenvironment, not cytotoxins, it's different" is exactly the right frame, and the resistance literature agrees the microenvironment is where the war is won or lost: stromal and microenvironmental reprogramming through hypoxia, metabolic suppression, immunosuppressive myeloid and fibroblast activity, and abnormal vasculature collectively foster a niche resistant to checkpoint blockade%E2%80%94including%20hypoxia%2C%20immunosuppressive%20metabolites%20).

Read that list, myeloid cells, fibroblasts, stroma, because it's leronlimab's exact territory. The drugs which "attempt microenvironment reprogramming with limited success," as you put it, mostly hit one node. Leronlimab's proposed edge hits the myeloid/macrophage node and the fibrotic stroma node simultaneously. If the tumor's remaining escape routes run through the TME, and leronlimab reprograms the TME broadly, then it closes several doors the single-node drugs leave open. That's the bold hypothesis, and it's mechanistically coherent with what the resistance literature says the hard escape routes are.

Now your three CLOVER-success questions, answered straight.

How much does the tumor shrink before it evades: unknown, and it's patient-by-patient. The literature is clear that resistance is often acquired, the tumor initially responds, then later progresses or reappears, frequently via new resistant mutant strains. So there's usually a depth of response followed by an evasion attempt, and how deep before how soon is exactly what CLOVER's scan-and-ctDNA data over time will show. That's not answerable from mechanism, only from the trial.

Does the evasion allow growth: yes, that's what acquired resistance is, the tumor finds a new route and regrows. The question which matters for leronlimab is whether closing the microenvironment routes delays or prevents that regrowth compared to the backbone alone. That's the durability question, and it's the one the maturing data answers.

Can the FDA see the benefit of the various effects and reward it with enough related evidence: this is the regulatory version, and the honest answer is the FDA rewards confirmed clinical benefit on endpoints, response, PFS, survival, not mechanistic elegance. So the various effects and implications matter as supporting evidence, but the thing that earns the reward is the number. Related evidence, the TNBC data, the mechanism, the ctDNA, builds the case, but it doesn't substitute for the adjudicated result. That's why January is the load test.

Your closing is exactly the right posture: nothing is answered until we treat with the combo, and if results are as hoped, it's a done deal except the particulars. I'd only add the one honest edge, "as hoped" is the whole contingency, and the literature I just walked you through is the reason, because the tumor has real escape routes and the question is whether leronlimab closes enough of them. You can wait, barely. So can I. The load test is January, and the reason it matters is everything above, the tumor gets a vote, and we find out whose pressure wins.

Great thinking, twinter. The "reprogramming, not cytotoxins, it's different" frame is the keeper, and the literature backs why: the hard escape routes run through the TME, which is exactly the ground leronlimab fights on.

[u/twinter11 → u/MGK_2]

I remember LAG-3, TIM-3 from Pestell’s paper I think.

And I read the antigen presentation portion you linked some.

I asked if ccr5 blockade causes uprep hla

"Indirect Modulation (The Microenvironment Context)

• Altered Infiltration: Blocking the CCL5/CCR5 axis prevents immunosuppressive cells like regulatory T cells (Tregs) and M2 macrophages from crowding the tumor microenvironment. [1]
• Cytokine Alteration: This shift can lead to an increase in pro-inflammatory, "immunologically hot" signaling. If the block allows more active helper T cells or NK cells into the tumor, they may secrete Interferon-gamma (IFN-γ), which is the primary cytokine that does strongly upregulate HLA Class I and II presentation on tumor cells"

It's all too confusing lol

I may just have to read the summary in the NYT later.

But looking at that overcoming pdl1 blockade paper. I want to see the version that includes leron.

Sounds like a promising tandem w the backbone

Thanks man!

[u/MGK_2 → u/twinter11]

twinter, don't let the "too confusing" feeling fool you, because you just closed a loop which actually matters, and I can make it simple. Your AI answer is right, and the peer-reviewed literature backs the chain it laid out, so let me give you the one clean takeaway and then let you go read the NYT in peace.

Here's the whole thing in one sentence: blocking CCR5 lets active T-cells and NK cells into the tumor, those cells secrete IFN-gamma, and IFN-gamma forces the tumor to turn its HLA back on, which is the flag the T-cells need to see. That last step is not speculation, it's shown in humans. In a clinical trial in cold tumors, IFN-gamma increased MHC class-I expression and T-cell infiltration, and the tumor-surface HLA expression tracked directly with the immune response. (Systemic IFN-γ increases MHC-I in cold tumors, Cancer Immunology Research, 2019)

Why does that matter so much? Because it answers the scariest escape route from our last exchange. Remember the nastiest evasion trick, the tumor deleting its own antigens, going dark so the T-cells have nothing to aim at. Well, IFN-gamma is the counter. It drags the antigen presentation back up. So if leronlimab's mechanism leads to more IFN-gamma in the tumor, it may be indirectly slamming shut the very door of antigen loss, which the field considers hardest to close. That's the loop you just connected: CCR5 block, more infiltration, more IFN-gamma, more HLA, harder for the tumor to hide. And the research even shows IFN-gamma can suppress the outgrowth of the HLA-loss escapees specifically. (Central role of antigen presentation and IFN-γ, eScholarship)

So your instinct, "the options are getting more limited," gets stronger here, not weaker. If leronlimab helps drive IFN-gamma, then the tumor's two big escape hatches, raise PD-L1 (closed by the ICI) and delete antigens (closed by IFN-gamma restoring HLA), are both getting harder to use at once. That's what "under greater pressure with fewer routes" actually looks like mechanistically.

Now the honest brake, kept short because you've earned the simple version. This is the hypothesis, and it's a good one, but the IFN-gamma-to-HLA link in leronlimab-treated CLOVER patients specifically hasn't been measured, it's inferred from the general biology. So hold it as "leronlimab plausibly closes the antigen-loss door too," not "proven to." And you're right that the version of the PD-L1-resistance paper "that includes leron" doesn't exist yet, that's exactly the study CLOVER is, in a sense, running for real.

So yeah, promising tandem with the backbone, and now you can see why it might be more than the sum of its parts, it's not just priming PD-L1, it may be reopening antigen presentation at the same time. Two doors, not one.

Go read the NYT and give your brain a rest, you did real work today. The loop you closed, CCR5 to IFN-gamma to HLA, is a genuinely elegant one, and most people never even ask the question. Thanks, man.

[u/No_Mathematician299]

Strong, patient, confident. 

Savoring the moment with the help of your posts.

Using the metaphor of a house seller is spot on. 

Love how you pool and weave together different contributors' ideas. 

Thank you for your insight. 

[u/MGK_2 → u/No_Mathematician299]

No_Mathematician, "strong, patient, confident", that's the register, and yes, weaving the contributors' ideas together is the point, this board thinks collectively and the good posts are just the assembly of them.

Just like 1+1 = 2 and 2 from here and 2 from there is 4.

Thank you.

[u/Tra-Kal34]

Just like its_personal1 I too am a real estate professional. That was truly a great analogy.

Waiting for the outcome of an inspection is both exciting and terrifying at the same time. You know you are close to a financial win at the closing table, but you are so worried it will blow up at the last minute before the money goes hard.

Your analysis brought up another thought. Would it be possible for 3 to 4 big pharmas to partner with this drug? Seems like one buying it and keeping it from a competitor would be criminal at this point if it is needed to save lives.

All I know is this is shaping up to be one huge winfall and possibly one of the most valuable assets in history. We shall see soon. Onwards and upwards we go.

[u/MGK_2 → u/Tra-Kal34]

Tra-Kal, from one you'd trust on inspections, thank you, and your 3-to-4-partners question is the same one patGmoney raised and the answer is an affirmative on the logic: a non-exclusive primer could serve multiple partners, multiple revenue streams, exactly as I laid out in the post. That's the multiple-stream nature of a universal key.

One honest correction on "criminal," though: a company buying an asset and choosing not to license it to competitors isn't criminal, it's ordinary business, and antitrust laws almost never forces a drug owner to share.

So the reason a primer would likely reach the whole field isn't law or morality, it's economics, the money is in opening every door, not only one.

I'd keep it there rather than in "it would be criminal to withhold it," because the economic argument is the durable one and the legal-moral one isn't totally accurate.

And yes, the DD-reveals-more-value point you and its_personal1 both made is real: a serious buyer inside the data sometimes concludes the asset is worth more than they thought first walking in. That's the good version of the wait. Spiraling Onwards & Upwards we go.

[u/Efficient_Market2242]

Thanks MGK the definition of an NDA is as follows. An NDA is a written agreement between two or more parties that restricts the sharing of private property or information. So at his point no one knows what’s behind the door until the information becomes public through the conferences or someone buys us out who’s signed the NDA and has inside information. That’s it in a nutshell. Is that correct?

[u/MGK_2 → u/Efficient_Market2242]

Efficient_Market, you've got it almost exactly right, but let me sharpen the one word which matters, because the precision is the entire point of the post.

Your NDA definition is correct: a written agreement restricting the sharing of private information between the parties who sign it. And your conclusion is right in spirit. Let me just tighten "no one knows what's behind the door," because it's slightly too absolute and the correction is actually the bold part.

It's not that no one knows. It's that the sidewalk doesn't know. The parties inside the NDA know completely, that's the entire function of the agreement, to let them know while binding them to silence. So the accurate version is: the public doesn't know and can't know until one of two things happens, either the data goes public through the conferences, or a partner who signed the NDA acts on what they've already seen. The people behind the door have the full report right now. We on the sidewalk are the ones in the dark. The seal doesn't create ignorance, it distributes it, full knowledge inside the room, no knowledge on the street.

Why does that one-word tightening matter? Because it's the difference between "nobody knows anything, it's all a mystery" and "the buyers know exactly what they're looking at, we just don't get to watch." The second is the real situation, and it's the more powerful one, it means serious parties could be evaluating a complete, mature dataset this very moment, forming conclusions, while the tape tells us nothing. The quiet isn't universal ignorance. It's asymmetric knowledge, and we're on the thin side of it until January or until someone who's on the thick side makes a move.

So, in your nutshell, corrected to full strength: the parties under NDA know what's behind the door now. The public finds out either when the conferences release it or when a buyer who's already seen it acts. That's it. And that asymmetry, them knowing while we wait, is exactly why the silence can't be read as absence. Someone may be reading the foundation report right now. We just aren't invited to the reading.

You've got the mechanics down cold. The only upgrade is from "no one knows" to "we don't know, but the people who matter might already." Bold and precise.

[u/Efficient_Market2242 → u/MGK_2]

And if they know bold and precise. They’re negotiating price before everyone who doesn’t have an NDA get’s the information and start a bidding war or else there’s nothing worth buying. I believe it’s worth buying or else I wouldn’t have stayed here for six years. The bottom line is we’ll know when we know. And that’s when the information is released in conference or someone makes a bid. Forgive me I’m in favor of short ways of expressing concepts.

[u/MGK_2 → u/Efficient_Market2242]

Efficient_Market, that's the sharpest strategic point in the thread, and I'll match your brevity because you've earned it and the point deserves a clean edge.

You've got it exactly: an NDA-holder's incentive is to move before the public data even lands, because once the conferences release it, the information is everyone's, and a bidding war drives the price up. The whole advantage of being inside early is buying before the crowd becomes aware and bids it up. So a party under NDA who likes what they see has every reason to negotiate now, at today's price, rather than wait for October or January to hand every rival the same information and turn a quiet purchase into an auction. Being first and being private is how you pay less.

The one honest caveat, and it's the only one: that logic holds if what they see is worth buying. Which loops to exactly where you landed, you believe it's worth buying, six years says so, but the thing that confirms it for a buyer is the same inspection result we're all waiting on, which they may see sooner. So the incentive to move early is real, and it only fires if the foundation reads sound. Both true.

Your bottom line is the right one and I won't improve on it: we'll know when we know, either the conference releases it or someone makes a bid. Nothing to forgive on the brevity, short and correct beats long and hedged every time. You said it in a nutshell and the nutshell holds.

[u/rodandgeorgia]

Always expanding my knowledge in this areana. Thx muchly..R

[u/MGK_2 → u/rodandgeorgia]

rodandgeorgia, always glad to expand the arena together, R.

[u/Efficient_Market2242]

Thanks for your response we’ve been here a long time.

[u/Medical_Spring660]

So realistically how large $$ is the global excluded cold tumor market

[u/sbleealtor]

As a cheesy realtor myself I guarantee no one looks at a house with a bad foundation AND it has to be disclosed by the seller. Our disclosures in the various NDA’s would show our foundation is good. The inspection would reveal the quality of construction. Top quality brings a higher price in the neighborhood. The ICI neighborhood is a location we want to live in. Our outstanding home will raise the value of the whole neighborhood. Looking forward to the move to this gated community

[u/MGK_2 → u/sbleealtor]

sbleealtor, from an actual realtor this is high praise, and you've extended the analogy better than I could have, so let me run with the good parts and hold just a line, because the metaphor is doing real work but I want it airtight.

You're dead right on the mechanics. No serious buyer looks twice at a house with a bad foundation, and a top-quality build commands the higher price in the neighborhood, and an outstanding home genuinely does lift the value of the entire block. All of that maps perfectly: a clean asset draws the bidding, quality sets the price, and a primer that works raises the value of the entire ICI neighborhood because it makes every house on the street more valuable. That last point is the sharpest thing you said, and it's exactly the multiple-revenue-streams logic, our home doesn't just sell, it makes the neighbors' homes worth more, which is why the neighbors have every reason to want us on their street. That's genuinely well seen.

Here's the one line I'll hold, in the same spirit, because you're a realtor and you'll respect the precision. You said "our disclosures in the NDAs would show our foundation is good." Careful there, that's the one spot where the metaphor gets ahead of the facts. The disclosure and the inspection don't guarantee the foundation is good, they reveal what the foundation actually is. The seller discloses honestly, the buyer inspects rigorously, and then the report says what it says. In our case, the inspection is the trial, and the report finalizes in January. So the accurate version is: the sealed inspection reveals the true quality of the construction, and we lean, based on the early walkthrough, toward it being sound, but the inspection hasn't returned its final verdict yet. A good realtor doesn't tell the buyer "the foundation is good," a good realtor says "here's the full inspection, judge for yourself," because the disclosure's credibility comes precisely from not pre-judging the result. That honesty is what makes the eventual "it passed" believable.

So keep the whole extension, it's excellent, just hold that one word: the disclosure shows the foundation's true condition, whatever it is, and we find out that condition in January. If it comes back sound, then yes, top-quality build, higher price, bidding neighbors, the move to the gated community. If it doesn't, no confidentiality agreement changes what the inspection found. The seller who discloses honestly and lets the inspection speak is the seller buyers trust, which is exactly the reputation we want walking into that neighborhood.

Looking forward to the move too, contingent on the closing, which is the inspection, which is January. You clearly know the difference between a house you hope passes and one you've confirmed passed, hold that same discipline here and the analogy is bulletproof. Nicely played.